Detection of a Distinct Erythropoietin (EPO) Profile After Isoelectric Focusing in Patients With Familial Erythrocytosis
Drug Testing and Analysis · 2026
DOI: 10.1002/dta.70049 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Testing and Analysis, 2026. Verfasst von Laurent Martin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire Antidopage Français (LADF), Université Paris-Saclay, Orsay, France. Hauptthemen laut MEDLINE: Erythropoietin, Polycythemia, Substance Abuse Detection. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Partnership for Clean Competition, Agence Nationale de la Recherche, Partnership for Clean Competition, 2018.
Abstract (Originalsprache)
Since the implementation of the first erythropoietin (EPO) detection method to fight the use of recombinant EPO (rEPO) for doping, the techniques used and identification criteria have evolved. The first technique involved iso‐electric focusing (IEF‐PAGE) to separate EPO isoforms by their charges. It can still be used for initial testing but is now largely replaced by electrophoretic separation based on molecular weight (SDS‐PAGE or SAR‐PAGE) to conclude decisively on the presence of rEPO. Recently, different mutations in the noncoding region of the EPO gene were identified in patients with familial erythrocytosis. Their blood EPO profiles after IEF‐PAGE were very basic and in the same area as rEPO. To avoid any possible misinterpretation in an antidoping context, the goal of this work was to characterize urine and blood EPO profiles from these patients using all methods authorized in antidoping laboratories (IEF‐PAGE, SDS‐PAGE, and SAR‐PAGE) and to compare them with wild‐type (WT) EPO and with profiles obtained after the administration of rEPO Eprex. Results showed that SDS‐PAGE and SAR‐PAGE profiles were not modified in the patients compared with WT EPO and could not be mistaken for the presence of rEPO. In contrast, the IEF‐PAGE profiles in urine were slightly more acidic than in blood and closer to the rEPO profile. However, they did not meet the identification criteria used when this technique was the only authorized method. It is highly unlikely that these EPO mutations, only identified in erythrocytosis patients yet, could lead to an adverse analytical finding.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratoire Antidopage Français (LADF), Université Paris-Saclay, Orsay, France.
- l'institut du thorax, Nantes Université, CNRS, INSERM, Nantes, France.
- Service d'Hématologie Biologique, Pôle Biologie, CHU de Dijon, Dijon, France.
- Laboratoire de Toxicologie, Centre Hospitalier Universitaire Tizi-Ouzou, Tizi-Ouzou, Algeria.
- Laboratoire d'Excellence GR-Ex, Paris, France.
- EPHE, PSL Université, Paris, France.
ORCID-Profile: Salam Idriss, Betty Gardie, Alexandre Marchand
Förderung
- Partnership for Clean Competition
- Agence Nationale de la Recherche
- Partnership for Clean Competition, 2018
Zitieren
APA
Martin, L., Idriss, S., Maaziz, N., Huerre, S., Mekacher, L. R., Lahmek, K., Girodon, F., Gardie, B., Ericsson, M., & Marchand, A. (2026). Detection of a Distinct Erythropoietin (EPO) Profile After Isoelectric Focusing in Patients With Familial Erythrocytosis. Drug Testing and Analysis. https://doi.org/10.1002/dta.70049
Vancouver
Martin L, Idriss S, Maaziz N, Huerre S, Mekacher LR, Lahmek K, et al. Detection of a Distinct Erythropoietin (EPO) Profile After Isoelectric Focusing in Patients With Familial Erythrocytosis. Drug Testing and Analysis. 2026. doi:10.1002/dta.70049
BibTeX
@article{Martin2026,
author = {Martin, Laurent and Idriss, Salam and Maaziz, Nada and Huerre, Soizic and Mekacher, Lamine Redouane and Lahmek, Kahina and Girodon, François and Gardie, Betty and Ericsson, Magnus and Marchand, Alexandre},
title = {Detection of a Distinct Erythropoietin (EPO) Profile After Isoelectric Focusing in Patients With Familial Erythrocytosis},
journal = {Drug Testing and Analysis},
year = {2026},
doi = {10.1002/dta.70049}
}
EUVIMED